Citi slashes Human Genome target on slow Benlysta sales

Doctors aren't flocking to Benlysta, the new lupus treatment developed by Human Genome Sciences ($HGSI) and marketed in partnership with GlaxoSmithKline ($GSK), Citi analyst Dr. Yaron Werber says in a new note to investors. As the Associated Press reports, Werber cut his price target on HGS stock to $15 from $26 on the slow uptake. Report